RNTX
Rein Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$79.60M
P/E Ratio
—
EPS
$-1.94
Beta
1.42
52W High
$2.40
52W Low
$1.00
50-Day MA
$1.38
200-Day MA
$1.31
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rein Therapeutics Inc
Rein Therapeutics Inc (RNTX) is a forward-thinking biopharmaceutical firm dedicated to pioneering next-generation therapies for neurodegenerative disorders. By harnessing its proprietary technology platform that fuses advanced neuroscience with innovative drug development, the company is well-positioned to tackle significant unmet medical needs through a robust pipeline of candidates. With a leadership team composed of industry veterans, Rein Therapeutics operates within a dynamic therapeutic landscape, making it an attractive opportunity for institutional investors focused on breakthrough healthcare advancements.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-21.93M |
| Operating Margin | 0.00% |
| Return on Equity | -139.90% |
| Return on Assets | -31.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-1.02 |
| Price-to-Book | 28.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $78.04M |
| Float | $21.45M |
| % Insiders | 4.56% |
| % Institutions | 40.58% |
Historical Volatility
HV 10-Day
154.59%
HV 20-Day
140.69%
HV 30-Day
126.82%
HV 60-Day
97.83%
HV Rank
99.6%
Volatility is currently expanding
More HEALTHCARE Stocks
Data last updated: 5/5/2026